Search Results
Results found for "Ralf Dechend"
- The Five Traps of Ignoring Kinetics
potency errors from premature reads ✅ Methods to detect hidden mechanisms—mixtures, dual effects, or time-dependent before they waste resources Classify antagonists by offset rate without waiting on PK data Spot time-dependent Kinetics in Drug Discovery: Your Edge If you’re still treating potency as a static number, you’re missing half
- Optimizing HTRF Assays with Fluorescent Ligands: Time-Resolved Fluorescence in GPCR Research
FRET is a distance-dependant energy transfer between a donor and an acceptor fluorophore, and in HTRF The donors used in this technique have longer half-lives than other fluorophores (between 300μs–1 ms
- 📰 GPCR Buzz: August 5-11, 2024 | Top Highlights from DrGPCR University!
News Nxera Pharma Operational Highlights and Consolidated Results for the Second Quarter and First Half
- 📰 GPCR Weekly News, September 25 to October 1, 2023
labeled receptors GPCR Binders, Drugs, and more Orthosteric ligand selectivity and allosteric probe dependence binding mode GPCRs in Cardiology, Endocrinology, and Taste An extracellular glucose sensor for substrate-dependent to Vertex for $48 million Merck KGgA collaborates with Exscientia plc in deal worth up to $674M 2023 Half-Year
- Advantages of Fluorescent Probes in GPCR Assays
However, over half of non-sensory GPCRs do not have drugs available in the clinic, opening the door to
- Enzyme Inhibition Pharmacology: The Hidden Gatekeepers of GPCR Drug Discovery
enzyme class is more important—or more unpredictable—than cytochrome P450s .CYP3A4 alone handles over half Probe-dependent. And responsible for countless drug–drug interactions. October 30 AMA Why Terry’s Corner The efficiency of your pipeline doesn’t hinge on one receptor—it depends
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
Roughly half of the receptors in the superfamily are sensory GPCRs, involved in olfaction, taste, vision ), meaning that lengthy pharmacodynamic activity is attained in vivo, despite the short circulatory half-life Twice-daily treatment with mOB-004 dose-dependently suppressed monocyte infiltration into the peritoneum






